Can AI be used in a GxP-regulated environment?
Yes, but AI that creates, changes or influences GxP records or quality decisions must be treated like any other regulated computerized system: risk-assessed for its intended use, validated or assured, access-controlled, and auditable under 21 CFR Part 11 and the applicable predicate rules. AI used only for non-GxP work, such as drafting internal emails, needs governance but not validation.
Draw the GxP boundary first
The first question is not which AI tool, but what the AI touches. If its output becomes, alters or decides on a record required by a predicate rule (batch records, deviations, CAPAs, clinical data, stability data, complaint files), it is in scope. If it drafts a meeting summary nobody relies on for a regulated decision, it is not.
Document that boundary in your AI policy and your system inventory so an inspector can see you made the call deliberately.
What FDA guidance says today
- Part 11 scope: FDA's Part 11 Scope and Application guidance (final, 2003) says FDA interprets Part 11 narrowly and recommends basing validation decisions on a risk assessment of a system's potential to affect product quality and safety.
- Computer software assurance: FDA's final guidance on Computer Software Assurance for Production and Quality Management System Software, issued February 2026 by CDRH and CBER, describes a risk-based approach to establishing confidence in automation used in medical device production or quality systems.
- AI for drug and biologic submissions: FDA's January 2025 guidance on using AI to support regulatory decision-making for drugs and biological products is still a draft. It proposes a risk-based credibility assessment framework for an AI model's context of use.
Practical controls for AI in GxP work
- Define the intended use and context of use for each AI function, and rate its risk.
- Validate or assure proportionate to risk, with test evidence you can show an inspector.
- Keep a human reviewer accountable for any AI-assisted GxP decision, and record that review.
- Lock model and configuration versions, and route changes through change control.
- Preserve audit trails, access control and record retention required by Part 11 and the predicate rules.
- Assess the vendor: data handling, training-data use, change notification and support for audits.
Generative AI needs extra care
General-purpose chat assistants change models frequently, and their output can vary for the same input. That makes them hard to validate for direct GxP use. Most companies start with assistive, human-reviewed uses outside the record, then move specific, locked-down functions into scope once they can show consistent performance. Keep the risk assessment, intended-use statement and test evidence together so the decision trail is easy to show during an inspection.
Common follow-up questions
Does ChatGPT or Copilot need to be validated?
Only for uses that fall inside GxP scope. Drafting non-regulated documents needs governance, not validation. If AI output becomes or decides on a GxP record, that specific use needs a risk-based validation or assurance approach and Part 11 controls.
Is FDA's AI guidance for drugs final?
No. As of October 2026, FDA lists its January 2025 guidance on AI to support regulatory decision-making for drug and biological products as a draft. Drafts signal FDA's thinking but are not for implementation until finalized.
Does Computer Software Assurance apply to pharma?
FDA's CSA guidance is written for medical device production and quality management system software under 21 CFR Part 820. Pharma and biotech teams often borrow its risk-based thinking, but should confirm applicability with their quality and regulatory leads.
LAN Service Group provides GxP-regulated IT for life-science companies, including AI governance, system inventories, access control and the IT controls that support validation and Part 11 audit trails.
Talk to LAN Service Group (888) 281-7243